Literature DB >> 11227670

Primary intestinal lymphangiectasia successfully treated with octreotide.

G Kuroiwa1, T Takayama, Y Sato, Y Takahashi, T Fujita, A Nobuoka, T Kukitsu, J Kato, S Sakamaki, Y Niitsu.   

Abstract

A 21-year-old man with diarrhea and edema was admitted to our hospital and diagnosed with protein-losing enteropathy caused by primary intestinal lymphangiectasia. He was placed, in turn, on a low-fat diet, an elemental diet, and, subsequently, fasting therapy with total parenteral nutrition (TPN) support. However, his symptoms were not relieved, but, rather were exacerbated. On the 45th day of hospitalization, octreotide therapy was initiated. After 2 weeks of treatment, his clinical symptoms, as well as hypoproteinemia and hypoalbuminemia, gradually became alleviated. The improvement was confirmed in terms of scintigraphy, endoscopy, and histology of the duodenum. The patient remained healthy until 6 months after the commencement of octreotide treatment, when he discontinued octreotide at his own discretion, at which point the symptoms recurred. Resumption of the drug, however, again brought about remission, which has continued until the present, March 2000. Thus, octreotide therapy is one modality which may be useful for refractory primary intestinal lymphangiectasia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11227670     DOI: 10.1007/s005350170142

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  22 in total

1.  Enteral nutrition as a primary therapy for intestinal lymphangiectasia: value of elemental diet and polymeric diet compared with total parenteral nutrition.

Authors:  Kunihiko Aoyagi; Mitsuo Iida; Takayuki Matsumoto; Shotaro Sakisaka
Journal:  Dig Dis Sci       Date:  2005-08       Impact factor: 3.199

2.  Anaemia in Waldmann's disease: A rare presentation of a rare disease.

Authors:  Shahira A El-Etreby; Ahmed Y Altonbary; Mohamed El Sorogy; Wagdi Elkashef; Jehan A Mazroa; Monir H Bahgat
Journal:  World J Gastrointest Endosc       Date:  2015-05-16

3.  How to treat an extensive form of primary intestinal lymphangiectasia?

Authors:  Rosana Troskot; Dragan Jurčić; Ante Bilić; Marija Gomerčić Palčić; Stanko Težak; Ivana Brajković
Journal:  World J Gastroenterol       Date:  2015-06-21       Impact factor: 5.742

4.  Clinical outcome of nutrition-oriented intervention for primary intestinal lymphangiectasia.

Authors:  Qing-Ya Tang; Jie Wen; Jiang Wu; Ying Wang; Wei Cai
Journal:  World J Pediatr       Date:  2010-12-30       Impact factor: 2.764

Review 5.  Primary intestinal lymphangiectasia: four case reports and a review of the literature.

Authors:  Jie Wen; Qingya Tang; Jiang Wu; Ying Wang; Wei Cai
Journal:  Dig Dis Sci       Date:  2010-03-03       Impact factor: 3.199

Review 6.  Imaging of fetal lymphangiectasias: prenatal and postnatal imaging findings.

Authors:  Christian A Barrera; Teresa Victoria; Fernando A Escobar; Ganesh Krishnamurthy; Christopher L Smith; Julie S Moldenhauer; David M Biko
Journal:  Pediatr Radiol       Date:  2020-11-30

7.  [Chronic diarrhea in a 43-year-old patient].

Authors:  J Strehl; M Schepke; E Wardelmann; W H Caselmann; T Sauerbruch
Journal:  Internist (Berl)       Date:  2003-05       Impact factor: 0.743

8.  Late-onset primary intestinal lymphangiectasia successfully managed with octreotide: a case report.

Authors:  Kotaro Suehiro; Noriyasu Morikage; Masanori Murakami; Osamu Yamashita; Kimikazu Hamano
Journal:  Ann Vasc Dis       Date:  2012-02-15

9.  Octreotide in Hennekam syndrome-associated intestinal lymphangiectasia.

Authors:  Siham Al Sinani; Yusria Al Rawahi; Hamed Abdoon
Journal:  World J Gastroenterol       Date:  2012-11-21       Impact factor: 5.742

10.  Successful treatment of protein-losing enteropathy induced by intestinal lymphangiectasia in a liver cirrhosis patient with octreotide: a case report.

Authors:  Hang Lak Lee; Dong Soo Han; Jin Bae Kim; Yong Chul Jeon; Joo Hyun Sohn; Joon Soo Hahm
Journal:  J Korean Med Sci       Date:  2004-06       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.